Unravelling the target landscape of tranylcypromines for new drug discovery
Acta Pharmaceutica Sinica B · 2025-06 · 15 (6) · 2985-3007
DOI: 10.1016/j.apsb.2025.04.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-06. Verfasst von Yihui Song und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan Province, Fujian Medical University.
Abstract (Originalsprache)
Molecular editing around privileged scaffolds, also known as periphery editing, is a commonly used strategy in contemporary drug discovery and development. Tranylcypromine (TCP) is a widely acknowledged scaffold with diverse pharmacological activities. TCP-derived compounds target different enzymes and cellular receptors such as amine oxidase, platelet P2Y12 receptor, and cytochrome P450 superfamily. These compounds have demonstrated various effects including antidepressant, anticancer, antiviral properties, involvement in prostaglandin synthesis, and mediation of drug metabolism. Notably, the first reversible oral P2Y12 receptor antagonist, ticagrelor, is currently used to prevent future myocardial infarction, stroke, and cardiovascular death. Several TCP-based lysine demethylase 1 (LSD1) inhibitors are currently undergoing clinical assessment. MIV-150, a third-generation non-nucleoside reverse transcriptase inhibitor, has progressed to the clinical stage for treating human immunodeficiency virus type 1 (HIV-1) seronegative patients suffering from acute coronary syndrome. This review aims to explore the target landscape of TCPs, highlight key structure-activity relationships (SARs), and emphasize the therapeutic potential of TCPs for treating various diseases. Finally, the lessons learned from our medicinal chemistry practice, challenges and future directions of TCP-based drug discovery are briefly discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fujian Medical University, Fuzhou 350122, China.
- College of Chemistry, Pingyuan Laboratory, Zhengzhou University, Zhengzhou 450001, China.
- Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
- Fujian Medical University
- Chunhui Project Foundation of the Education Department of China
- Ministry of Education of the People's Republic of China
Zitieren
APA
Song, Y., Chang, J., & Yu, B. (2025). Unravelling the target landscape of tranylcypromines for new drug discovery. Acta Pharmaceutica Sinica B, 15(6), 2985-3007. https://doi.org/10.1016/j.apsb.2025.04.012
Vancouver
Song Y, Chang J, Yu B. Unravelling the target landscape of tranylcypromines for new drug discovery. Acta Pharmaceutica Sinica B. 2025;15(6):2985-3007. doi:10.1016/j.apsb.2025.04.012
BibTeX
@article{Song2025,
author = {Song, Yihui and Chang, Junbiao and Yu, Bin},
title = {Unravelling the target landscape of tranylcypromines for new drug discovery},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {6},
pages = {2985--3007},
doi = {10.1016/j.apsb.2025.04.012}
}
EUVIMED